{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:46:41Z","timestamp":1772117201049,"version":"3.50.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11523-018-0566-1","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T01:43:53Z","timestamp":1524793433000},"page":"269-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and\/or Leptomeningeal Disease"],"prefix":"10.1007","volume":"13","author":[{"given":"Maximilian","family":"Hochmair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"issue":"25","key":"566_CR1","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1200\/JCO.2005.03.145","volume":"23","author":"Corey J. Langer","year":"2005","unstructured":"Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23(25):6207\u201319.","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"566_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1634\/theoncologist.12-7-884","volume":"12","author":"A. F. Eichler","year":"2007","unstructured":"Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12(7):884\u201398.","journal-title":"The Oncologist"},{"key":"566_CR3","first-page":"1789","volume":"6","author":"Y Fan","year":"2013","unstructured":"Fan Y, Huang Z, Fang L, Miu L, Lin N, Gong L, et al. Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco Targets Ther. 2013;6:1789\u2013803.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"566_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","volume":"10","author":"Petra Hoffknecht","year":"2015","unstructured":"Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schutz M, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156\u201363.","journal-title":"Journal of Thoracic Oncology"},{"issue":"8","key":"566_CR5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1200\/JCO.2005.04.6185","volume":"24","author":"Deepak Khuntia","year":"2006","unstructured":"Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24(8):1295\u2013304.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"566_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/1097-0142(196503)18:3<298::AID-CNCR2820180306>3.0.CO;2-H","volume":"18","author":"Neil B. Ruderman","year":"1965","unstructured":"Ruderman N, Hall R. Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer. 1965;18:298\u2013306.","journal-title":"Cancer"},{"issue":"2","key":"566_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8","volume":"48","author":"Solomon Zimm","year":"1981","unstructured":"Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981;48(2):384\u201394.","journal-title":"Cancer"},{"issue":"10055","key":"566_CR8","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"P Mulvenna","year":"2016","unstructured":"Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004\u201314.","journal-title":"Lancet"},{"issue":"9422","key":"566_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","volume":"363","author":"DW Andrews","year":"2004","unstructured":"Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665\u201372.","journal-title":"Lancet"},{"issue":"2","key":"566_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","volume":"29","author":"M Kocher","year":"2011","unstructured":"Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134\u201341.","journal-title":"J Clin Oncol"},{"issue":"8","key":"566_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199002223220802","volume":"322","author":"RA Patchell","year":"1990","unstructured":"Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494\u2013500.","journal-title":"N Engl J Med"},{"issue":"3","key":"566_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.prro.2011.12.004","volume":"2","author":"MN Tsao","year":"2012","unstructured":"Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2(3):210\u201325.","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"566_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","volume":"5","author":"B Gleissner","year":"2006","unstructured":"Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5(5):443\u201352.","journal-title":"Lancet Neurol"},{"issue":"3","key":"566_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","volume":"89","author":"JL Kuiper","year":"2015","unstructured":"Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer. 2015;89(3):255\u201361.","journal-title":"Lung Cancer"},{"issue":"4","key":"566_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11864-012-0206-4","volume":"13","author":"S Nagpal","year":"2012","unstructured":"Nagpal S, Riess J, Wakelee H. Treatment of leptomeningeal spread of NSCLC: a continuing challenge. Curr Treat Options in Oncol. 2012;13(4):491\u2013504.","journal-title":"Curr Treat Options in Oncol"},{"issue":"18","key":"566_CR16","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","volume":"74","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010;74(18):1449\u201354.","journal-title":"Neurology"},{"issue":"5","key":"566_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","volume":"8","author":"HS Gwak","year":"2013","unstructured":"Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol. 2013;8(5):599\u2013605.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"566_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","volume":"7","author":"PG Morris","year":"2012","unstructured":"Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7(2):382\u20135.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"566_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.currproblcancer.2007.07.001","volume":"31","author":"WP O\u2019Meara","year":"2007","unstructured":"O\u2019Meara WP, Borkar SA, Stambuk HE, Lymberis SC. Leptomeningeal metastasis. Curr Probl Cancer. 2007;31(6):367\u2013424.","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"566_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/cncr.22399","volume":"109","author":"L Moscetti","year":"2007","unstructured":"Moscetti L, Nelli F, Felici A, Rinaldi M, De Santis S, D\u2019Auria G, et al. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by outcome research network for evaluation of treatment results in oncology. Cancer. 2007;109(2):274\u201381.","journal-title":"Cancer"},{"issue":"7","key":"566_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1023\/A:1008318515795","volume":"10","author":"PE Postmus","year":"1999","unstructured":"Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 1999;10(7):753\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"566_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(01)00622-2","volume":"3","author":"IJ Fidler","year":"2002","unstructured":"Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3(1):53\u20137.","journal-title":"Lancet Oncol."},{"issue":"5422","key":"566_CR23","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","volume":"284","author":"J Holash","year":"1999","unstructured":"Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284(5422):1994\u20138.","journal-title":"Science"},{"issue":"25","key":"566_CR24","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.2013.49.8915","volume":"31","author":"Vijaya R. Bhatt","year":"2013","unstructured":"Bhatt VR, Kedia S, Kessinger A, Ganti AK. Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations. J Clin Oncol. 2013;31(25):3162\u20134.","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"566_CR25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/neuonc\/noq076","volume":"12","author":"A. F. Eichler","year":"2010","unstructured":"Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12(11):1193\u20139.","journal-title":"Neuro-Oncology"},{"issue":"35","key":"566_CR26","doi-asserted-by":"crossref","first-page":"56998","DOI":"10.18632\/oncotarget.10933","volume":"7","author":"G Han","year":"2016","unstructured":"Han G, Bi J, Tan W, Wei X, Wang X, Ying X, et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget. 2016;7(35):56998\u20137010.","journal-title":"Oncotarget"},{"issue":"1","key":"566_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2014.01.006","volume":"84","author":"L.E.L. Hendriks","year":"2014","unstructured":"Hendriks LE, Smit EF, Vosse BA, Mellema WW, Heideman DA, Bootsma GP, et al. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? Lung Cancer. 2014;84(1):86\u201391.","journal-title":"Lung Cancer"},{"issue":"4","key":"566_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","volume":"20","author":"T Iuchi","year":"2015","unstructured":"Iuchi T, Shingyoji M, Itakura M, Yokoi S, Moriya Y, Tamura H, et al. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol. 2015;20(4):674\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"566_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","volume":"9","author":"DY Shin","year":"2014","unstructured":"Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9(2):195\u20139.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"566_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2478\/raon-2014-0016","volume":"48","author":"K Stanic","year":"2014","unstructured":"Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol. 2014;48(2):173\u201383.","journal-title":"Radiol Oncol"},{"issue":"2","key":"566_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","volume":"99","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neuro-Oncol. 2010;99(2):283\u20136.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"566_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3892\/mco.2013.190","volume":"2","author":"Y Deng","year":"2014","unstructured":"Deng Y, Feng W, Wu J, Chen Z, Tang Y, Zhang H, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2(1):116\u201320.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"566_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/JTO.0b013e3181d899bb","volume":"6","author":"A Hata","year":"2011","unstructured":"Hata A, Kaji R, Fujita S, Katakami N. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol. 2011;6(3):653\u20134.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"566_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1097\/JTO.0b013e318294c8e8","volume":"8","author":"E Lee","year":"2013","unstructured":"Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol. 2013;8(8):1069\u201374.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"566_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","volume":"70","author":"Y Togashi","year":"2012","unstructured":"Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70(3):399\u2013405.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"566_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.lungcan.2012.05.092","volume":"77","author":"S.J. Park","year":"2012","unstructured":"Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556\u201360.","journal-title":"Lung Cancer"},{"issue":"3","key":"566_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.lungcan.2008.12.011","volume":"65","author":"Jeong-Eun Kim","year":"2009","unstructured":"Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65(3):351\u20134.","journal-title":"Lung Cancer"},{"key":"566_CR38","unstructured":"Zhang JX, Cai D, Li SY, Zhou CZ, Qin YY, Ouyang M. Clinical comparison of erlotinib and gefitinib in non-small cell lung cancer with brain metastases. Chin J Cancer Prevent Treat. 2015;22:285\u20138."},{"issue":"2","key":"566_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","volume":"82","author":"T. Iuchi","year":"2013","unstructured":"Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82(2):282\u20137.","journal-title":"Lung Cancer"},{"issue":"3","key":"566_CR40","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","volume":"12","author":"G. J. Riely","year":"2006","unstructured":"Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3 Pt 1):839\u201344.","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"566_CR41","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","volume":"12","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(13):3908\u201314.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"566_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cncr.30990","volume":"124","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, Daras M, et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer. 2018;124(1):105\u20139.","journal-title":"Cancer"},{"issue":"2","key":"566_CR43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/annonc\/mdw556","volume":"28","author":"HA Yu","year":"2017","unstructured":"Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran B, Cross J, et al. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol. 2017;28(2):278\u201384.","journal-title":"Ann Oncol"},{"key":"566_CR44","first-page":"282","volume":"71","author":"D d\u2019Avella","year":"1998","unstructured":"d\u2019Avella D, Cicciarello R, Angileri FF, Lucerna S, La Torre D, Tomasello F. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir Suppl. 1998;71:282\u20134.","journal-title":"Acta Neurochir Suppl"},{"key":"566_CR45","doi-asserted-by":"crossref","unstructured":"van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep. 2002;9(4):683\u20138.","DOI":"10.3892\/or.9.4.683"},{"key":"566_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-319-24223-1_7","volume":"893","author":"A Ahsan","year":"2016","unstructured":"Ahsan A. Mechanisms of resistance to EGFR tyrosine kinase inhibitors and therapeutic approaches: an update. Adv Exp Med Biol. 2016;893:137\u201353.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"566_CR47","first-page":"475","volume":"18","author":"J Li","year":"2015","unstructured":"Li J, Wu X, Wang Z, Shen Z, Sun N, Zhu X. Ionizing radiation reduces TKI resistance caused by T790M mutation in NSCLC cell lines. Zhongguo Fei Ai Za Zhi. 2015;18(8):475\u201380.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"10","key":"566_CR48","first-page":"2884","volume":"5","author":"T Akimoto","year":"1999","unstructured":"Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 1999;5(10):2884\u201390.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"566_CR49","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-04-3547","volume":"65","author":"P Chinnaiyan","year":"2005","unstructured":"Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65(8):3328\u201335.","journal-title":"Cancer Res"},{"issue":"7","key":"566_CR50","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","volume":"15","author":"GL Ceresoli","year":"2004","unstructured":"Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15(7):1042\u20137.","journal-title":"Ann Oncol"},{"key":"566_CR51","doi-asserted-by":"crossref","unstructured":"Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N, et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst. 2014;106(7):ii.","DOI":"10.1093\/jnci\/dju151"},{"issue":"5","key":"566_CR52","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.ijrobp.2008.10.026","volume":"74","author":"JS Lind","year":"2009","unstructured":"Lind JS, Lagerwaard FJ, Smit EF, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1391\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"566_CR53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.lungcan.2008.10.028","volume":"65","author":"S Ma","year":"2009","unstructured":"Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer. 2009;65(2):198\u2013203.","journal-title":"Lung Cancer"},{"issue":"7","key":"566_CR54","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1200\/JCO.2011.40.1174","volume":"31","author":"JW Welsh","year":"2013","unstructured":"Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31(7):895\u2013902.","journal-title":"J Clin Oncol"},{"key":"566_CR55","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2147\/DDDT.S53011","volume":"7","author":"H Zhuang","year":"2013","unstructured":"Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther. 2013;7:1179\u201386.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"566_CR56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2010.01.018","volume":"70","author":"I Olmez","year":"2010","unstructured":"Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P, Xu Y. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer. 2010;70(2):174\u20139.","journal-title":"Lung Cancer"},{"issue":"3","key":"566_CR57","doi-asserted-by":"publisher","first-page":"909","DOI":"10.7314\/APJCP.2012.13.3.909","volume":"13","author":"YD Zeng","year":"2012","unstructured":"Zeng YD, Zhang L, Liao H, Liang Y, Xu F, Liu JL, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac J Cancer Prev. 2012;13(3):909\u201314.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"8","key":"566_CR58","doi-asserted-by":"crossref","first-page":"13304","DOI":"10.18632\/oncotarget.14515","volume":"8","author":"Q Zhu","year":"2017","unstructured":"Zhu Q, Sun Y, Cui Y, Ye K, Yang C, Yang D, et al. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). Oncotarget. 2017;8(8):13304\u201311.","journal-title":"Oncotarget"},{"key":"566_CR59","first-page":"76","volume":"3","author":"I Sullivan","year":"2016","unstructured":"Sullivan I, Planchard D. Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Front Med (Lausanne). 2016;3:76.","journal-title":"Front Med (Lausanne)"},{"issue":"20","key":"566_CR60","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","volume":"58","author":"Q Zeng","year":"2015","unstructured":"Zeng Q, Wang J, Cheng Z, Chen K, Johnstrom P, Varnas K, et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem. 2015;58(20):8200\u201315.","journal-title":"J Med Chem"},{"issue":"368","key":"566_CR61","doi-asserted-by":"publisher","first-page":"368ra172","DOI":"10.1126\/scitranslmed.aag0976","volume":"8","author":"Z Yang","year":"2016","unstructured":"Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016;8(368):368ra172.","journal-title":"Sci Transl Med"},{"issue":"15_suppl","key":"566_CR62","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2017.35.15_suppl.2020","volume":"35","author":"James Chih-Hsin Yang","year":"2017","unstructured":"Yang JC-H, Cho BC, Kim D-W, Kim S-W, Lee J-S, Su W-C, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study. J Clin Oncol. 2017;35(suppl 18):abst 2020.","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"566_CR63","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1200\/JCO.2017.35.15_suppl.2069","volume":"35","author":"Byoung Chul Cho","year":"2017","unstructured":"Cho BC, Ahn M-J, Lee J-S, Kim D-W, Kim S-W, John T, et al. Phase I study (BLOOM) of AXD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy. J Clin Oncol. 2017;35(suppl 18):abst 2069.","journal-title":"Journal of Clinical Oncology"},{"key":"566_CR64","doi-asserted-by":"crossref","unstructured":"Ahn M-J, Kim D-W, Cho BC, Kim S-W, Lee J-S, Ahn JS, et al. Phase I study (BLOOM) of AXD3759, a BBB penetrable EGFR inhibitor, in TKI na\u00efve EGFRm NSCLC patients in CNS metastases. J Clin Oncol. 2017;35(suppl 18):abst 2006.","DOI":"10.1200\/JCO.2017.35.15_suppl.2006"},{"issue":"11","key":"566_CR65","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"Yi-Long Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u20131466","journal-title":"The Lancet Oncology"},{"key":"566_CR66","unstructured":"Piccioni D. A Phase II Study of Dacomitinib in Progressive Brain Metastases. https:\/\/www.clinicaltrialsgov\/ct2\/show\/study\/NCT02047747?view=record , 2016."},{"issue":"9","key":"566_CR67","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046\u201361.","journal-title":"Cancer Discov"},{"issue":"34","key":"566_CR68","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1038\/onc.2008.109","volume":"27","author":"D Li","year":"2008","unstructured":"Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702\u201311.","journal-title":"Oncogene"},{"issue":"2","key":"566_CR69","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F. Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342\u201350.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"12","key":"566_CR70","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40262-013-0091-4","volume":"52","author":"Sven Wind","year":"2013","unstructured":"Wind S, Schmid M, Erhardt J, Goeldner RG, Stopfer P. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet. 2013;52(12):1101\u20139.","journal-title":"Clinical Pharmacokinetics"},{"issue":"3","key":"566_CR71","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","volume":"11","author":"M Schuler","year":"2016","unstructured":"Schuler M, Wu YL, Hirsh V, O\u2019Byrne K, Yamamoto N, Mok T, et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11(3):380\u201390.","journal-title":"J Thorac Oncol"},{"key":"566_CR72","doi-asserted-by":"crossref","unstructured":"Yufen X, Binbin S, Wenyu C, Jialiang L, Xinmei Y. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus. 2016;5(1):1244.","DOI":"10.1186\/s40064-016-2873-2"},{"issue":"2","key":"566_CR73","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/aps.2016.107","volume":"38","author":"SR Zhang","year":"2017","unstructured":"Zhang SR, Zhu LC, Jiang YP, Zhang J, Xu RJ, Xu YS, et al. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacol Sin. 2017;38(2):233\u201340.","journal-title":"Acta Pharmacol Sin"},{"issue":"27","key":"566_CR74","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"Lecia V. Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327\u201334.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"566_CR75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"Yi-Long Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213\u201322.","journal-title":"The Lancet Oncology"},{"issue":"2","key":"566_CR76","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"James Chih-Hsin Yang","year":"2015","unstructured":"Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141\u201351.","journal-title":"The Lancet Oncology"},{"issue":"5","key":"566_CR77","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577\u201389.","journal-title":"Lancet Oncol"},{"issue":"9","key":"566_CR78","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/CAD.0000000000000410","volume":"27","author":"M Hochmair","year":"2016","unstructured":"Hochmair M, Holzer S, Burghuber OC. Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases. Anti-Cancer Drugs. 2016;27(9):914\u20135.","journal-title":"Anti-Cancer Drugs"},{"issue":"11","key":"566_CR79","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2217\/fon-2017-0636","volume":"14","author":"Nicolas Girard","year":"2018","unstructured":"Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol. 2018: https:\/\/doi.org\/10.2217\/fon-2017-0636 .","journal-title":"Future Oncology"},{"issue":"8","key":"566_CR80","first-page":"4177","volume":"37","author":"A Tamiya","year":"2017","unstructured":"Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T, et al. Cerebrospinal fluid penetration rate and efficacy of Afatinib in patients with EGFR mutation-positive non-small cell lung Cancer with leptomeningeal Carcinomatosis: a multicenter prospective study. Anticancer Res. 2017;37(8):4177\u201382.","journal-title":"Anticancer Res"},{"issue":"15_suppl","key":"566_CR81","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.2017.35.15_suppl.2008","volume":"35","author":"Richard D. Baird","year":"2017","unstructured":"Baird RD, Garcia-Corbacho J, Linossi C, Kumar SS, Smith D, Williams M, et al. Cambridge Brain Mets Trial 1 (CamBMT1). A proof of principle study of afatinib penetration into cerebral metastases (mets) for patients (pts) undergoing neurosurgical resection, combined with prior low-dose, targeted radiotherapy (RT). Phase 1b results. J Clin Oncol. 2017;35(18_suppl):abst 2008.","journal-title":"Journal of Clinical Oncology"},{"key":"566_CR82","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fonc.2017.00088","volume":"7","author":"C Eze","year":"2017","unstructured":"Eze C, Hegemann NS, Roengvoraphoj O, Dantes M, Manapov F. Concurrent Afatinib and whole-brain radiotherapy in exon 19-del-EGFR mutant lung adenocarcinoma: a case report and mini review of the literature. Front Oncol. 2017;7:88.","journal-title":"Front Oncol"},{"issue":"41","key":"566_CR83","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001739","volume":"94","author":"SH Li","year":"2015","unstructured":"Li SH, Hsieh MH, Fang YF. Afatinib in treatment-naive patients with EGFR-mutated lung adenocarcinoma with brain metastasis: a case series. Medicine (Baltimore). 2015;94(41):e1739.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"566_CR84","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/14737140.2018.1409623","volume":"18","author":"SH Li","year":"2018","unstructured":"Li SH, Liu CY, Hsu PC, Fang YF, Wang CC, Kao KC, et al. Response to afatinib in treatment-naive patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Rev Anticancer Ther. 2018;18(1):81\u20139.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"566_CR85","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.bulcan.2016.12.006","volume":"104","author":"M Ghosn","year":"2017","unstructured":"Ghosn M, Assi T, El Rassy E, Moussa T, Kattan J. An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents. Bull Cancer. 2017;104(4):385\u20137.","journal-title":"Bull Cancer"},{"issue":"3","key":"566_CR86","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000454727","volume":"62","author":"Y Kawaguchi","year":"2017","unstructured":"Kawaguchi Y, Hanaoka J, Hayashi H, Mizusaki N, Iihara H, Itoh Y, et al. Clinical efficacy of afatinib treatment for a patient with leptomeningeal carcinomatosis. Chemotherapy. 2017;62(3):147\u201350.","journal-title":"Chemotherapy"},{"issue":"3","key":"566_CR87","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.lungcan.2014.06.002","volume":"85","author":"CH Lin","year":"2014","unstructured":"Lin CH, Lin MT, Kuo YW, Ho CC. Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis. Lung Cancer. 2014;85(3):479\u201380.","journal-title":"Lung Cancer"},{"key":"566_CR88","doi-asserted-by":"crossref","unstructured":"Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T, et al. Afatinib efficacy and cerebrospinal fluid concentration in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis. Ann Oncol. 2016;27(suppl 6):abst 1241P.","DOI":"10.1093\/annonc\/mdw383.41"},{"key":"566_CR89","doi-asserted-by":"crossref","unstructured":"Saijo T, Ito T, Ikeda N. Three cases of\u00a0EGFR mutation-positive lung adenocarcinoma with leptomeningeal Carcinomatosis successfully treated with Afatinib. Haigan. 2016;56(4):290\u20136.","DOI":"10.2482\/haigan.56.290"},{"issue":"75","key":"566_CR90","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"L. V. Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.","journal-title":"Science Translational Medicine"},{"issue":"12","key":"566_CR91","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","volume":"35","author":"JC-H Yang","year":"2017","unstructured":"Yang JC-H, Ahn M-J, Kim D-W, Ramalingam SS, Sequist LV, Su W-C, et al. Osimertinib in pretreated T790M-positive advanced non\u2013small-cell lung Cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288\u201396.","journal-title":"J Clin Oncol"},{"issue":"7","key":"566_CR92","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"18","key":"566_CR93","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA Janne","year":"2015","unstructured":"Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689\u201399.","journal-title":"N Engl J Med"},{"issue":"2","key":"566_CR94","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2017","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2017;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"20","key":"566_CR95","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130\u201340.","journal-title":"Clin Cancer Res"},{"key":"566_CR96","doi-asserted-by":"crossref","unstructured":"Goss G, Tsai C-M, Shepherd F, Ahn M-J, Bazhenova L, Crin\u00f2 L, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two Phase II trials. J Thorac Oncol. 2017;12(1):S440\u2013S1;abst MA16.11.","DOI":"10.1016\/j.jtho.2016.11.514"},{"issue":"15_suppl","key":"566_CR97","doi-asserted-by":"publisher","first-page":"9005","DOI":"10.1200\/JCO.2017.35.15_suppl.9005","volume":"35","author":"Tony Mok","year":"2017","unstructured":"Mok T, Ahn M, Han J. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3). J Clin Oncol. 2017;35(suppl 15):9005.","journal-title":"Journal of Clinical Oncology"},{"key":"566_CR98","doi-asserted-by":"crossref","unstructured":"Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Cobo Dols MA, Cho EK, et al. CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. Ann Oncol. 2017;28(suppl 10):abstract LBA5.","DOI":"10.1093\/annonc\/mdx729.007"},{"issue":"10","key":"566_CR99","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","volume":"26","author":"D Planchard","year":"2015","unstructured":"Planchard D, Loriot Y, Andre F, Gobert A, Auger N, Lacroix L, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26(10):2073\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"566_CR100","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.jtho.2015.12.093","volume":"11","author":"HN Song","year":"2016","unstructured":"Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung Cancer. J Thorac Oncol. 2016;11(4):e45\u20137.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"566_CR101","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560\u20132.","journal-title":"Nat Med"},{"key":"566_CR102","volume":"25","author":"SS Ramalingam","year":"2017","unstructured":"Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung Cancer. J Clin Oncol. 2017;25:JCO2017747576.","journal-title":"J Clin Oncol"},{"issue":"3","key":"566_CR103","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1183\/09031936.00195609","volume":"37","author":"R. Porta","year":"2010","unstructured":"Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624\u201331.","journal-title":"European Respiratory Journal"},{"key":"566_CR104","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1752-1947-8-64","volume":"8","author":"S Ohara","year":"2014","unstructured":"Ohara S, Ushijima T, Gunji M, Tanai C, Tanaka Y, Noda H, et al. Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report. J Med Case Rep. 2014;8:64.","journal-title":"J Med Case Rep"},{"issue":"2","key":"566_CR105","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1183\/09031936.00162307","volume":"33","author":"AM Ruppert","year":"2009","unstructured":"Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, et al. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J. 2009;33(2):436\u201340.","journal-title":"Eur Respir J"},{"issue":"11","key":"566_CR106","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","volume":"4","author":"T Katayama","year":"2009","unstructured":"Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009;4(11):1415\u20139.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"566_CR107","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","volume":"5","author":"MJ Ahn","year":"2017","unstructured":"Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5(11):891\u2013902.","journal-title":"Lancet Respir Med"}],"updated-by":[{"DOI":"10.1007\/s11523-018-0598-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T00:00:00Z","timestamp":1538438400000}}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0566-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T09:29:33Z","timestamp":1604222973000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0566-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0566-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11523-018-0598-6","asserted-by":"object"}]},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,27]]},"assertion":[{"value":"27 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Enhanced digital features were retrospectively added to this article.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Open Access publication of this article was funded by Boehringer Ingelheim. This work was supported by Boehringer Ingelheim. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Helen Kitchen and Hashem Dbouk of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this article. Boehringer Ingelheim was involved in the preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MJH has received speaker fees from MSD, BMS, AstraZeneca, Roche, Lilly, and Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}